These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 21426837)
1. [Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs]. He XG Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):101-4. PubMed ID: 21426837 [TBL] [Abstract][Full Text] [Related]
2. Preservatives in eyedrops: the good, the bad and the ugly. Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969 [TBL] [Abstract][Full Text] [Related]
3. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe]. Levrat F; Pisella PJ; Baudouin C J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349 [TBL] [Abstract][Full Text] [Related]
4. [Managing treatment side effects: the respective roles of the active ingredient and the preservative]. Aptel F; Denis P; Baudouin C J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364 [TBL] [Abstract][Full Text] [Related]
5. [Ocular surface injury resulted from topical anti-glaucoma medications: prevention and cure]. Ouyang PB; Duan XC Zhonghua Yan Ke Za Zhi; 2012 Jun; 48(6):557-61. PubMed ID: 22943813 [TBL] [Abstract][Full Text] [Related]
6. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Baudouin C Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications. Liu X; Yu FF; Zhong YM; Guo XX; Mao Z Chin Med J (Engl); 2015 Sep; 128(18):2444-9. PubMed ID: 26365960 [TBL] [Abstract][Full Text] [Related]
8. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302 [TBL] [Abstract][Full Text] [Related]
9. [Glaucoma and ocular surface]. Stefan C; Cojocaru I; Pop A Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383 [TBL] [Abstract][Full Text] [Related]
10. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Hommer A; Mohammed Ramez O; Burchert M; Kimmich F Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs? Baudouin C Int J Clin Pharmacol Res; 1996; 16(1):29-41. PubMed ID: 9001927 [TBL] [Abstract][Full Text] [Related]
12. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Baudouin C; Pisella PJ; Fillacier K; Goldschild M; Becquet F; De Saint Jean M; Béchetoille A Ophthalmology; 1999 Mar; 106(3):556-63. PubMed ID: 10080214 [TBL] [Abstract][Full Text] [Related]
13. [Ocular intolerance to antiglaucoma medications is underestimated]. Bresson-Dumont H Bull Soc Belge Ophtalmol; 2010; (315):47-53. PubMed ID: 21114054 [TBL] [Abstract][Full Text] [Related]
14. [Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication]. Nenciu A; Stefan C; Ardelean C Oftalmologia; 2004; 48(1):35-42. PubMed ID: 15279417 [TBL] [Abstract][Full Text] [Related]
15. [Advances in preservative-free glaucoma drops]. Stefan C; Pop A; Cojocaru I Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063 [TBL] [Abstract][Full Text] [Related]
16. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study. Liang H; Baudouin C; Labbe A; Riancho L; Brignole-Baudouin F PLoS One; 2012; 7(3):e33913. PubMed ID: 22442734 [TBL] [Abstract][Full Text] [Related]
17. [Morphological alterations induced by preservatives in eye drops]. Huber-van der Velden KK; Thieme H; Eichhorn M Ophthalmologe; 2012 Nov; 109(11):1077-81. PubMed ID: 23179812 [TBL] [Abstract][Full Text] [Related]
18. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Ammar DA; Noecker RJ; Kahook MY Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433 [TBL] [Abstract][Full Text] [Related]
20. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]